Eli Lilly (LLY) - Get Eli Lilly and Company Report shares moved higher Monday after the drugmaker published final data from a major clinical trial that showed a reduction in heart failure risk for patients with type-2 diabetes.
The five-year study found that Jardiance, which Eli Lilly is developing with Germany's Boehringer Ingelheim, showed a 40% reduction in "relative risk of all-cause mortality", compared to patients using standard DPP-4 inhibitors, as well as a 12% reduction in the risk of the myocardial infarction, or stroke risks in adults with type 2 diabetes in routine care.
Jardiance, which was first approved as a diabetes treatment by the U.S. Food and Drug Administration in 2014, generated around $420 million in sales for Eli Lilly last quarter, a 34% increase from the same period last year.
https://www.thestreet.com/markets/eli-lilly-stock-gains-on-impressive-data-from-diabetes-drug-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.